Clinical Trial Update: Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating serplulimab in combination with chemotherapy as neoadjuvant therapy for resectable non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: NSCLC, Neoadjuvant Therapy | Phase 2 | Status: ACTIVE_NOT_RECRUITING